# Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

> **NCT03169985** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 280 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
- **DRUG:** Rosuvastatin 20 mg orally once a day

## Key facts

- **NCT ID:** NCT03169985
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-12
- **Primary completion:** 2027-01-28
- **Final completion:** 2027-01-28
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03169985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03169985, "Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03169985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*